20-F: CytoMed Therapeutics Limited Navigates Financial Landscape with 2023 Annual Report

CytoMed Therapeutics Limited's 2023 annual report reveals ongoing R&D investments and strategic financial management amidst operating losses.

Summary

• CytoMed Therapeutics Limited's 2023 annual report provides an overview of the company's financial performance and strategic direction.
• The company is focused on developing cell-based immunotherapies for cancer and degenerative diseases.
• CytoMed has not generated revenue from commercial sales and incurred a loss of S$4.13 million in 2023.
• Research and development expenses totaled S$1.59 million, reflecting continued investment in product candidates.
• The company completed an offering in April 2023, resulting in net proceeds of approximately S$10.31 million.
• CytoMed is pursuing clinical trials for its lead product candidate, CTM-N2D, and advancing pre-clinical activities for other candidates.
• The company's cGMP facility in Malaysia supports manufacturing for clinical trials.
• CytoMed is managing intellectual property through licensing agreements and trade secrets.
• The company faces competition in the biopharmaceutical industry and is subject to regulatory requirements in Singapore and Malaysia.
• CytoMed's financial statements are prepared in accordance with IFRS.
• The company's ability to continue as a going concern is dependent on obtaining sufficient additional funding to finance its operations.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is making progress in its clinical trials and has a strong cash position, it is also incurring losses and faces significant risks and competition.

Positives

• The company completed an offering in April 2023, raising net proceeds of S$10.31 million, strengthening its financial position.
• CytoMed's lead product candidate, CTM-N2D, is advancing through clinical trials, indicating progress in its development pipeline.
• The company's cGMP facility in Malaysia supports manufacturing for clinical trials, providing control over production.
• CytoMed has a research collaboration agreement with Sengkang General Hospital to advance injectable allogeneic umbilical cord derived MSC for cartilage injury.

Negatives

• CytoMed Therapeutics Limited reported a loss of S$4.13 million for the year ended December 31, 2023.
• The company has not generated revenue from commercial sales and expects to incur losses for the foreseeable future.
• The company relies on licensing agreements with ATPL for key technologies, which could be a risk if the agreements are terminated.
• The company is subject to regulatory requirements in Singapore and Malaysia, which could increase compliance costs.

Risks

• The company's ability to continue as a going concern is dependent on obtaining sufficient additional funding to finance its operations.
• Clinical trials may experience delays or may not progress to clinical trials, which would adversely affect the ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all.
• The company may fail to successfully compete with academic institutions and other biopharmaceutical companies that are developing similar product candidates or alternatives to cellular immunotherapy product candidates.
• The company may incur substantial liabilities as a result of product liability lawsuits, if any, against us and this could limit commercialization of any product candidate that we may develop.
• The company's cGMP Facility may be affected by circumstances beyond our control, such as natural disasters, and we may be required to cease operations and manufacturing of our product candidates
• The company is exposed to information technology and cyber security risks and disruption of service.
• The company may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from commercializing or increase the costs of commercializing our product candidates.
• The company may not be able to obtain and enforce our intellectual property rights throughout the world.
• The company may not be able to meet our commercialization milestones in our patent license agreements with ATPL, and if our license agreement is terminated as a result, our clinical trials and business will be significantly affected.
• The company may face claims for infringing, misappropriating or otherwise violating intellectual property rights of third parties or engaging in unfair competition, which would be expensive and time-consuming, and could hinder the successful development and/or commercialization our product candidates.
• The company will need to increase the size of our organization, and we may experience difficulties in managing growth.
• The company may not identify or develop other product candidates and may fail to capitalize on programs or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success.
• The company may not identify or develop other product candidates and may fail to capitalize on programs or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success.
• The company may not be able to attract and retain senior management, clinical, and key scientific personnel, we may be unable to successfully develop our product candidates, conduct our clinical trials and commercialize our product candidates.
• The company may face securities class action litigation.
• The company may lose our foreign private issuer status, which would then require us to comply with the Exchange Acts domestic reporting regime and cause us to incur additional legal, accounting and other expenses.
• The company may fail to maintain an effective system of internal control over financial reporting in the future, we may not be able to accurately report our financial condition, results of operations or cash flows, which may adversely affect investor confidence.
• The company is subject to the laws of Singapore, which differ in certain material respects from the laws of the United States.
• The company is subject to the political, economic and social conditions in the jurisdiction of Malaysia.
• The company is subject to the foreign exchange legislation and regulations in the jurisdiction of Malaysia.
• The company is subject to regulations governing foreign workers in the event of employment of such foreign workers.
• The company is subject to costs and risks associated with the monitoring, rehabilitation and compliance with environmental laws and regulations.
• The company may face similar risks for our applications in foreign jurisdictions.
• The company may face securities class action litigation.
• The company may face securities class action litigation.

Future Outlook

The company expects to continue to incur losses for the foreseeable future and will focus on advancing its product candidates through clinical development.

Industry Context

The company operates in the competitive field of immunotherapy for cancer treatment, facing competition from well-funded biopharmaceutical companies and research institutions.

Comparison to Industry Standards

• The company's approach to cell therapy differs from existing CAR-T therapies by utilizing allogeneic, off-the-shelf platforms based on gamma delta T cells and iPSCs.
• Competitors in the allogeneic CAR-T therapy space include Allogene Therapeutics, Bristol-Myers Squibb, and Gilead Sciences.
• The company's gamma delta T cell product candidate may face competition from other cell-based immunotherapy approaches derived from NK cells and T cells.
• Competitors in the iPSC-derived immune cells space include Fate Therapeutics and Century Therapeutics.

Related Party Transactions

• CHOO Chee Kong provided a personal guarantee for credit facilities obtained by CytoMed Malaysia.
• CHOO Chee Kong and Messiah Limited executed personal and corporate guarantees, respectively, in favor of mDR Limited guaranteeing the obligations of the Company under the mDR Convertible Loan.
• The then-shareholders of the Company agreed to a waiver of their pre-emption rights to allot and issue certain numbers of shares to Glorious Finance Limited.
• The then-shareholders of the Company agreed to a waiver of their pre-emption rights to allot and issue certain numbers of shares to Dr Lucas LUK Tien Wee.
• The Company entered into a subscription agreement with Glorious Finance Limited in relation to its subscription of ordinary shares in our Company.
• The Company entered into a subscription agreement with mDR Limited in relation to its subscription of ordinary shares in our Company.
• CHOO Chee Kong and mDR Limited also executed a put option agreement, allowing mDR Limited to have the right and option to require CHOO Chee Kong to purchase and acquire a certain number of shares in our Company from mDR Limited.
• The Company entered into an investment agreement with LMC, as varied by a supplemental agreement and a further supplemental letter, to acquire new ordinary shares representing 20.0% of the total number of shares in LMC at a subscription consideration of RM1.50 million.
• Puricell entered into a license agreement with ATPL, under which ATPL granted Puricell and its affiliates a worldwide, fee bearing, royalty bearing, non-exclusive, non-sublicensable, non-transferable and revocable-for-cause license to use ATPLs GMP-compatible reprogramming of human blood cells know-how.
• ATPL granted us and our affiliates, a non-exclusive, royalty-free, fee bearing, non-transferable, non-sublicensable, and revocable-for-cause license to use modified human K562 cells in the territories of Singapore and Malaysia for internal academic, research or investigation only.

Stakeholder Impact

• Shareholders may experience dilution if the company issues additional equity securities.
• The company's success depends on the acceptance of its product candidates by physicians, patients, third-party payors, and others in the medical community.
• Employees are subject to insider trading policies and may face disciplinary action for violations.
• The company's operations are subject to regulatory requirements in Singapore and Malaysia, which could impact its ability to conduct business.

Next Steps

• Advance CTM-N2D through clinical development.
• Advance additional product candidates to clinical trials, including CTM-N2D, iPSC-gdNKT, CTM-GDT and CTM-MSC.
• Discover and develop additional product candidates.
• Establish and validate our own clinical-scale and commercial-scale cGMP facilities.
• Initiate or develop a MAA, or equivalent in the relevant countries, for CTM-N2D, iPSC-gdNKT, CTM-GDT and CTM-MSC and/or seek marketing approvals for any of our other product candidates that successfully complete clinical trials.
• Engage, on an as needed basis, third-party contractors including CROs and CMOs to conduct clinical trials.
• Maintain, expand and protect our intellectual property portfolio.
• Acquire or in-license other product candidates and technologies.
• Explore new partnerships locally, within the region and globally.

Key Dates

Keywords

CytoMed Therapeutics, cell therapy, immunotherapy, clinical trials, financial results, CTM-N2D, iPSC-gdNKT, CGMP Facility, regulatory approvals, biopharmaceutical